Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Karen Stanek

Physical Medicine & Rehabilitation Spokane, WA Medical Doctor

NPI 1225017411 CMS profile 55721

1315 N Division St, Spokane, WA 99202

Open in the dashboard

General payments

$18,983

154 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Karen Stanek of Spokane, WA is reported in the CMS Open Payments database as having received $18,983 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $9,740 6
2023 General $1,026 4
2022 General $262 13
2021 General $962 35
2020 General $2,455 51
2019 General $4,538 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karen Stanek
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Karen Stanek were reported at $0. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Karen Stanek Physical Medicine & Rehabilitation median Middle half National median
2019 $4,538 $133 $45–$390 $163
2020 $2,455 $88 $29–$272 $114
2021 $962 $116 $33–$360 $132
2022 $262 $123 $40–$378 $149
2023 $1,026 $131 $43–$396 $160
2024 $9,740 $141 $45–$409 $164
2025 $0 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Ipsen Biopharmaceuticals, Inc $16,711 33 payments
  2. Allergan Inc. $515 30 payments
  3. Collegium Pharmaceutical, Inc. $263 17 payments
  4. Lilly USA, LLC $250 14 payments
  5. Merz North America, Inc. $165 7 payments
  6. Merz Pharmaceuticals, LLC $156 6 payments
  7. Amgen Inc. $154 5 payments
  8. Smith+Nephew, Inc. $100 4 payments
  9. Biohaven Pharmaceuticals, Inc. $82 5 payments
  10. Saol Therapeutics Inc. $79 2 payments
  11. Other $507 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,030 8 payments
  2. Food and Beverage $3,465 142 payments
  3. Travel and Lodging $1,429 3 payments
  4. Education $59 1 payment
Products named General payments · program years 2019–2024
  1. DYSPORT $16,711 33 payments
  2. Xeomin $321 13 payments
  3. XTAMPZA $263 17 payments
  4. BOTOX $260 17 payments
  5. EMGALITY $250 14 payments
  6. UBRELVY $213 11 payments
  7. AIMOVIG $197 8 payments
  8. REYVOW $117 6 payments
  9. NURTEC ODT $109 7 payments
  10. Santyl $89 3 payments
  11. Other $602 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$60,153

Medicare's payments for the services billed

Medicare patients

31

Average age 72

Services billed

586

11 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Diabetes 39%
Cancer 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $9,740
$9,740 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record